Sarepta Therapeutics (SRPT) is a publicly traded Healthcare sector company. As of May 21, 2026, SRPT trades at $17.25 with a market cap of $1.80B and a P/E ratio of 23.37. SRPT moved +2.88% today. Year to date, SRPT is -18.75%; over the trailing twelve months it is -57.19%. Its 52-week range spans $10.42 to $138.81. Analyst consensus is neutral with an average price target of $21.64. Rallies surfaces SRPT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Sarepta Therapeutics Posts $331M Q1 Profit, $730.8M Revenue Beat But Elevidys Demand Slumps: Sarepta Therapeutics reported Q1 net income of $331 million and adjusted earnings of $3.16 per share, beating consensus estimates of $0.90. The company generated revenue of $730.8 million versus $467.9 million forecast, but weaker-than-expected Elevidys demand weighed on investor sentiment.
| Metric | Value |
|---|---|
| Price | $17.25 |
| Market Cap | $1.80B |
| P/E Ratio | 23.37 |
| EPS | $0.73 |
| Dividend Yield | 0.00% |
| 52-Week High | $138.81 |
| 52-Week Low | $10.42 |
| Volume | 2.49K |
| Avg Volume | 0 |
| Revenue (TTM) | $2.18B |
| Net Income | $65.06M |
| Gross Margin | 0.00% |
24 analysts cover SRPT: 0 strong buy, 6 buy, 13 hold, 5 sell, 0 strong sell. Consensus rating is neutral. Average price target: $21.64.